We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Phosphorylation Turns a Tumor Suppressor into a Promoter of Cancer Development

By LabMedica International staff writers
Posted on 03 Aug 2016
Cancer researchers have determined the molecular mechanism by which a modification to the protein encoded by the RUNX3 gene turns a tumor suppressor into a promoter of cancer development and progression.

There are three mammalian RUNX genes, RUNX1, RUNX2, and RUNX3, all of which are associated with oncogenic activities. More...
While RUNX3 is a key tumor suppressor in many tissue types such as gastric, colon and bladder, it promotes oncogenesis in ovarian and skin cancers. The RUNX3 gene encodes a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence found in a number of enhancers and promoters and can either activate or suppress transcription. It usually functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer.

Investigators at the National University of Singapore (Singapore) reported in the May 23, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that the phosphorylation of the threonine 173 (T173) residue within the Runt domain of RUNX3 disrupted RUNX DNA binding activity during mitotic entry to facilitate the recruitment of RUNX proteins to mitotic structures. Moreover, knockdown of RUNX3 delayed mitotic entry.

Phosphorylation of the RUNX3 protein was found to be carried out by the Aurora kinase enzyme, which is present in unusually high levels in some cancers. Phosphorylation prevented the binding of RUNX3 to DNA, resulting in RUNX3 relocating to centrosomes where it promoted uncontrolled cell division.

”Unlike other modifications which stem from changes to the RUNX3 DNA itself or how DNA is read, phosphorylation does not accompany any changes in the DNA and is hence undetectable at the genetic level. Given that modifications such as phosphorylation are likely to be impermanent and reversible, the clinical implications are far ranging. Moving forward, the team is looking into ways to assess the feasibility of enhancing RUNX tumor suppression or inhibiting RUNX mitotic function to kill rapidly proliferating cancer cells,” said senior author Dr. Yoshiaki Ito, professor of medical oncology at the National University of Singapore.

Related Links:
National University of Singapore



New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.